Pseudomonas Aeruginosa Infection
15
2
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.7%
1 terminated out of 15 trials
88.9%
+2.4% vs benchmark
40%
6 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
Development and Validation of (Bio)Sensors for the Identification of Pathogens
Early Optimization of Ceftazidime Regimen in Critical Care
Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection
Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa